A BC Platforms (BCP) partnership that features Finland’s Euformatics and Hungary’s Oncompass Drugs has been awarded a contract for the second section of growing standardized oncology workflows for a purchaser consortium of seven European hospitals, represented by the Medical College Graz. 

The consortium is fashioned by hospitals from the Medical College of Graz in Austria, College of Florence and College of Milano-Bicocca in Italy, Erasmus College Medical Heart within the Netherlands, Christian-Albrecht College of Kiel and St. Anna Kids’s Most cancers Analysis Institute in Germany, and the Centre Léon Bérard in France.

This follows on from the announcement in Might 2022 in regards to the three corporations forming a partnership to ship section 1 of this Instand-NGS4P undertaking.

Instand-NGS4P is a Horizon 2020 funded undertaking that shares BCP’s imaginative and prescient for enhancing most cancers sufferers’ diagnostics. That is achieved by growing and offering built-in and standardized workflows for subsequent technology sequencing (NGS) and integrating info from most cancers gene testing, pharmacogenetics testing and e-medication, to help medical determination making. This system will run, with three phases, till Might 2025 with a complete pre-commercial procurement funds of roughly €8 million ($8.2 million).

Contract award

BCP, Euformatics, and Oncompass Drugs, have been engaged on designing the answer. After a assessment of submitted reviews from numerous suppliers for section 1, and the functions for section 2 relating to prototyping, the partnership has been awarded the section 2 contract. The mix of present IP and experience in areas similar to genomic knowledge administration, variant interpretation, NGS knowledge high quality management, and precision oncology, was elementary to the partnership being awarded the contract.

Kurt Zatloukal, Professor of Pathology on the Medical College Graz, mentioned: “Part considered one of this necessary undertaking to ship progressive NGS workflows, pushed by affected person and medical wants, has come a good distance since our final announcement in Might. The consortium of BC Platforms, Euformatics and Oncompass Drugs was chosen from a number of extremely aggressive functions, which have been assessed in a multi-step peer-reviewed course of. We’re trying ahead to persevering with this stimulating collaboration in section two.” 

Tero Silvola, CEO of BC Platforms, mentioned: “I’m delighted that the excellent high quality of the work on this vital Horizon 2020 funded undertaking, ensuing from our shut partnership with the gifted groups at Euformatics, and Oncompass Drugs, has been recognised with a contract for section two. That is about serving to outline the medical practices for oncology and precision medication for years to return. We’re proud that our genomic knowledge administration platform is taking part in an element in making healthcare higher, alongside Euformatics’s experience in variant interpretation and high quality management, and Oncompass Drugs’s robust contribution to the e-medication a part of this system.”

Pushing the envelope

Tommi Kaasalainen, CEO of Euformatics, added: “We’re delighted with one other win in partnership with BC Platforms, having deployed medical options collectively in North America, Europe, and Asia. Oncompass Drugs has been a superb addition to the partnership, offering vital worth. We’ll be persevering with with this successful trio in section two of the Instand-NGS4P program, which is able to construct on prime of the Euformatics Genomics Hub providing in shut collaboration with main European healthcare establishments.” 

Istvan Petak, founder and CEO of Oncompass Drugs, mentioned: “I mentioned again in Might we’re trying ahead to pushing the envelope, and I’m delighted with how far we’ve been in a position to go, working intently with our companions. We wish to present an end-to-end answer for oncologists to search out the correct focused remedy for each most cancers affected person primarily based on the entire complicated molecular profile of their tumor. This partnership will make it simple for hospitals to deploy higher NGS providers, and sufferers have higher therapies, lengthy after the undertaking is accomplished.”

The second section of the undertaking begins now, with outcomes due in January 2024. The hospital buying consortium will then consider the output of all section 2 contractors and choose these to proceed to section 3 to finally deploy and combine in 2025 two standardized NGS workflows as the results of the Instand-NGS4P program.

Source link